Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Common Equity (2016 - 2025)

Sonoma Pharmaceuticals has reported Common Equity over the past 15 years, most recently at $3.4 million for Q4 2025.

  • For Q4 2025, Common Equity fell 29.53% year-over-year to $3.4 million; the TTM value through Dec 2025 reached $3.4 million, down 29.53%, while the annual FY2025 figure was $4.4 million, 28.12% down from the prior year.
  • Common Equity for Q4 2025 was $3.4 million at Sonoma Pharmaceuticals, down from $3.8 million in the prior quarter.
  • Over five years, Common Equity peaked at $11.5 million in Q3 2021 and troughed at $3.4 million in Q4 2025.
  • A 5-year average of $6.3 million and a median of $5.6 million in 2022 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: crashed 56.67% in 2021 and later surged 72.24% in 2022.
  • Year by year, Common Equity stood at $11.2 million in 2021, then tumbled by 50.23% to $5.6 million in 2022, then grew by 20.38% to $6.7 million in 2023, then decreased by 27.23% to $4.9 million in 2024, then decreased by 29.53% to $3.4 million in 2025.
  • Business Quant data shows Common Equity for SNOA at $3.4 million in Q4 2025, $3.8 million in Q3 2025, and $4.1 million in Q2 2025.